

Visual Analog Scales in Formats Other than a 10 Centimeter Horizontal Line to Assess Pain and Other Clinical Data

THEODORE PINCUS, MARTIN BERGMAN, TUULIKKI SOKKA, JILL ROTH, CHRISTOPHER SWEARINGEN, and YUSUF YAZICI

ABSTRACT. Objective. To analyze visual analog scales (VAS) for pain and patient global estimate on a Multidimensional Health Assessment Questionnaire (MDHAQ) in formats other than a traditional 10 cm horizontal line, designed to facilitate scoring on MDHAQ in usual clinical care.

Methods. The MDHAQ with VAS for pain and global estimate was completed by each patient at each visit. VAS formats other than a traditional (unnumbered) 10 cm horizontal line based on 21 circles at 0.5 intervals were analyzed. Formats included unnumbered, symbol at the 11th circle, numbers and/or squares (instead of circles) at selected intermittent scores, and numbers at each circle. Analyses were performed to study the time to score MDHAQ with different VAS formats, possible "clustering" of responses in any format, particularly with intermittent numbers and/or symbols, and test-retest reliability of various formats.

Results. The median time to score MDHAQ with a 10 cm line VAS was 15.6 seconds, compared to 7.4 seconds for the 21 numbered circle VAS. No other format was scored in fewer seconds. Clustering was seen for scores of VAS formats with intermittent numbers or symbols, which rendered them unsuitable for use. No clustering was seen for the 21 numbered circle VAS format, for which test-retest agreement was significant, and similar to the 10 cm line VAS format.

Conclusion. A 21 numbered circle VAS may be a desirable alternative to a 10 cm horizontal line, yielding similar results and requiring less than half the time to score. (First Release June 15 2008; J Rheumatol 2008;35:1550-8)

Key Indexing Terms:

VISUAL ANALOG SCALES
PATIENT GLOBAL STATUS

PAIN
RHEUMATOID ARTHRITIS

Measurement of pain on a visual analog scale (VAS) was established as a valuable quantitative clinical assessment in the 1970s by Huskisson and colleagues^{1,2}. The VAS format has been extended to assess patient global estimate of status, fatigue, functional status³⁻⁵, and other patient problems⁶, as well as to a physician/assessor estimate of global status. Two VAS scores for pain and patient estimate of global status are included in the American College of Rheumatology (ACR) Core Data Set^{7,8}, and are found on the Health Assessment

Questionnaire (HAQ)³ and its multidimensional version (MDHAQ)^{4,9}.

Pain and patient global estimate VAS scores are included in all rheumatoid arthritis (RA) clinical trials and most clinical research. However, pain and global status VAS have not been assessed quantitatively at the majority of visits in usual care, as patient questionnaires are not completed at most visits to rheumatologists¹⁰. One potential reason involves the time required to use a ruler to measure the distance from the left border of a traditional 10 cm line VAS. Further, the length of a 10 cm VAS may be distorted in printing and photocopying, and some patients have difficulty with a 10 cm line VAS¹¹. A VAS of 21 squares or circles in 0.5 unit increments can be scored quickly without a ruler, overcoming these limitations.

Early reports indicated that a 10 cm horizontal line without numbering provided an optimal format for a pain VAS, compared to vertical, numbered, and other formats designed to facilitate scoring^{1,2,12}. Therefore, formal studies appeared necessary to compare results using other formats to the traditional 10 cm horizontal line. This report presents comparisons of the 10 cm horizontal line VAS to other VAS formats, including 21 circles at 0.5 intervals, unnumbered or num-

From the NYU Hospital for Joint Diseases, New York, New York; Taylor Hospital, Ridley Park, Pennsylvania, USA; Jyväskylä Central Hospital, Jyväskylä, and Medcare Oy, Äänekoski, Finland; Baylor College of Medicine, Houston, Texas; and Medical University of South Carolina, Charleston, South Carolina, USA.

Supported in part by grants from Amgen, Bristol-Myers Squibb, the Arthritis Foundation, and the Jack C. Massey Foundation.

T. Pincus, MD, NYU Hospital for Joint Diseases; M. Bergman, MD, Taylor Hospital; T. Sokka, MD, PhD, Jyväskylä Central Hospital and Medcare Oy; J. Roth, BS, Baylor College of Medicine; C. Swearingen, MS, Medical University of South Carolina; Y. Yazici, MD, NYU Hospital for Joint Diseases.

Address reprint requests to Dr. T. Pincus, NYU-Hospital for Joint Diseases, 301 East 17 Street, New York, NY 10003, USA.

E-mail: tedpincus@gmail.com

Accepted for publication March 19, 2008.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2008. All rights reserved.

Multi-Dimensional Health Assessment Questionnaire (R783-NP2)

This questionnaire includes information not available from blood tests, X-rays, or any source other than you. Please try to answer each question, even if you do not think it is related to you at this time. Try to complete as much as you can yourself, but if you need help, please ask. There are no right or wrong answers. Please answer exactly as you think or feel. Thank you.

FOR OFFICE USE ONLY

1. Please check (✓) the ONE best answer for your abilities at this time:

OVER THE LAST WEEK, were you able to:	Without ANY Difficulty	With SOME Difficulty	With MUCH Difficulty	UNABLE To Do
a. Dress yourself, including tying shoelaces and doing buttons?	0	1	2	3
b. Get in and out of bed?	0	1	2	3
c. Lift a full cup or glass to your mouth?	0	1	2	3
d. Walk outdoors on flat ground?	0	1	2	3
e. Wash and dry your entire body?	0	1	2	3
f. Bend down to pick up clothing from the floor?	0	1	2	3
g. Turn regular faucets on and off?	0	1	2	3
h. Get in and out of a car, bus, train, or airplane?	0	1	2	3
i. Walk two miles or three kilometers, if you wish?	0	1	2	3
j. Participate in recreational activities and sports as you would like, if you wish?	0	1	2	3
k. Get a good night's sleep?	0	1.1	2.2	3.3
l. Deal with feelings of anxiety or being nervous?	0	1.1	2.2	3.3
m. Deal with feelings of depression or feeling blue?	0	1.1	2.2	3.3

2. How much pain have you had because of your condition OVER THE PAST WEEK?

Please indicate below how severe your pain has been:

NO PAIN 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10 PAIN AS BAD AS IT COULD BE

3. Please place a check (✓) in the appropriate spot to indicate the amount of pain you are having today in each of the joint areas listed below:

	None	Mild	Moderate	Severe		None	Mild	Moderate	Severe
a. LEFT FINGERS	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	i. RIGHT FINGERS	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
b. LEFT WRIST	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	j. RIGHT WRIST	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
c. LEFT ELBOW	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	k. RIGHT ELBOW	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
d. LEFT SHOULDER	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	l. RIGHT SHOULDER	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
e. LEFT HIP	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	m. RIGHT HIP	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
f. LEFT KNEE	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	n. RIGHT KNEE	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
g. LEFT ANKLE	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	o. RIGHT ANKLE	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
h. LEFT TOES	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	p. RIGHT TOES	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
q. NECK	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	r. BACK	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3

4. Considering all the ways in which illness and health conditions may affect you at this time, please indicate below how you are doing:

VERY WELL 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10 VERY POORLY

Please turn to the other side

For Office Use Only: RAPID 3	RAPID 3 (0-10)	RAPID 4	RAPID 4 (0-10)
NR: 1=0.3, 2=0.7, 3=1.0 LS: 4=1.3, 5=1.7, 6=2.0 MS: 7=2.3, 8=2.7, 9=3.0, 10=3.3, 11=3.7, 12=4.0 HS: 13=4.3, 14=4.7, 15=5.0, 16=5.3, 17=5.7, 18=6.0, 19=6.3, 20=6.7, 21=7.0, 22=7.3, 23=7.7, 24=8.0, 25=8.3, 26=8.7, 27=9.0, 28=9.3, 29=9.7, 30=10.0	<input type="checkbox"/>	NR: 1=0.3, 2=0.5, 3=0.8, 4=1.0 LS: 5=1.3, 6=1.5, 7=1.8, 8=2.0 MS: 9=2.3, 10=2.5, 11=2.8, 12=3.0, 13=3.3, 14=3.5, 15=3.8, 16=4.0 HS: 17=4.3, 18=4.5, 19=4.8, 20=5.0, 21=5.3, 22=5.5, 23=5.8, 24=6.0, 25=6.3, 26=6.5, 27=6.8, 28=7.0, 29=7.3, 30=7.5, 31=7.8, 32=8.0, 33=8.3, 34=8.5, 35=8.7, 36=9.0, 37=9.3, 38=9.5, 39=9.8, 40=10.0	<input type="checkbox"/>
RAPID 5 (0-10)	NR: 1=0.2, 2=0.4, 3=0.6, 4=0.8 5=1.0 LS: 6=1.2, 7=1.4, 8=1.6, 9=1.8, 10=2.0 MS: 11=2.2, 12=2.4, 13=2.6, 14=2.8, 15=3.0, 16=3.2, 17=3.4, 18=3.6, 19=3.8, 20=4.0 HS: 21=4.2, 22=4.4, 23=4.6, 24=4.8, 25=5.0, 26=5.2, 27=5.4, 28=5.6, 29=5.8, 30=6.0, 31=6.2, 32=6.4, 33=6.6, 34=6.8, 35=7.0, 36=7.2, 37=7.4, 38=7.6, 39=7.8, 40=8.0, 41=8.2, 42=8.4, 43=8.6, 44=8.8, 45=9.0, 46=9.2, 47=9.4, 48=9.6, 49=9.8, 50=10.0		RAPID 5 (0-50)

1.a-j FN (0-10)

1=0.3 16=3.3
2=0.7 17=5.7
3=1.0 18=6.0
4=1.3 19=6.3
5=1.7 20=6.7
6=2.0 21=7.0
7=2.3 22=7.3
8=2.7 23=7.7
9=3.0 24=8.0
10=3.3 25=8.3
11=3.7 26=8.7
12=4.0 27=9.0
13=4.3 28=9.3
14=4.7 29=9.7
15=5.0 30=10

2.PN (0-10)

4.PTGL (0-10)

RAPID 3 (0-30)

3.a-p PTJT (0-10)

1=0.2 25=5.2
2=0.4 26=5.4
3=0.6 27=5.6
4=0.8 28=5.8
5=1.0 29=6.0
6=1.3 30=6.3
7=1.5 31=6.4
8=1.7 32=6.7
9=1.9 33=6.9
10=2.1 34=7.1
11=2.3 35=7.3
12=2.5 36=7.5
13=2.7 37=7.7
14=2.9 38=7.9
15=3.1 39=8.1
16=3.3 40=8.3
17=3.5 41=8.5
18=3.8 42=8.8
19=4.0 43=9.0
20=4.2 44=9.2
21=4.4 45=9.4
22=4.6 46=9.6
23=4.8 47=9.8
24=5.0 48=10

RAPID 4 (0-40)

MDGLOBAL (0-100)

RAPID 5 (0-50)

Copyright: Health Report Services, Inc., www.mdhaq.org

Figure 1. Multidimensional Health Assessment Questionnaire (MDHAQ). The front page includes 10 activities for function and 2 visual analog scales (VAS) for pain and patient global estimate of status, and a self-report joint count from a Rheumatoid Arthritis Disease Activity Index (RADAI). Scoring templates for these measures are available on the right side. The reverse side (not shown) includes a review of systems, fatigue VAS, demographic data, and recent medical history. Copyright© Health Report Services, Hastings-on-Hudson, NY, USA.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2008. All rights reserved.

concern, however, that use of intermittent numbers or different symbols might introduce “clustering,” defined, as noted, as scores designated by 5% or more patients at positions with an intermittent number or different symbol compared to responses on a VAS with only circles. Formats reported here in studies of possible clustering included VAS versions T-5 and T-7 compared to T-3 (Figure 2); additional formats studied were not informative beyond the reported formats.

Test-retest reliability. MDHAQ versions with VAS in the traditional 10 cm line and the 21 numbered circle format, which was found to require the fewest seconds to score and not be affected by clustering of responses (see Results), were selected for studies of test-retest reliability. The 2 MDHAQ were completed within 1 hour, according to 4 different protocols: 10 cm line first and 21 circles second; 21 circles first and 10 cm line second; 10 cm line first and 10 cm line second; and 21 circles first and 21 circles second. Spearman rank-order correlations and intraclass correlations (ICC) were estimated as a measure of test-retest reliability. To assess the agreement between test and retest scores, the Bland-Altman¹⁷ method was used. Mean differences between test and retest scores, its standard deviation (SD), 95% confidence interval around the difference between the test and retest values, and scatterplot graphs were computed according to this method. The smallest detectable difference (SDD) was also calculated, which is defined as 1.96 times the SD of the difference between VAS scores. The percentages of retest responses within 0.5, 1, and 2 units of the test responses were calculated as an indication of scale agreement.

RESULTS

Time to score MDHAQ with different VAS formats. The median time for the 3 rheumatologists to score a traditional 10 cm MDHAQ with a ruler (T-1) was 15.6 seconds (Table 1), compared to 10.4 seconds for 21 unnumbered circles (T-2), and 7.4 seconds for 21 numbered circles (T-3), a little less than half the time required to score with a ruler. A format in which a mark was available only at the midpoint of the VAS (T-4) required a median time of 8.6 seconds, 1.2 seconds longer than with all circles numbered. A VAS with squares at 0, 2, 4, 6, 8, 10, and circles at all other scores (T-5) required a median of 10.2 seconds, similar to the 10.4 seconds for 21 unnumbered circles. A VAS with diamonds (T-6) at positions 2.0, 4.0, and 6.5 required a median of 8.3 seconds (Table 1). (Format T-7 was not studied formally for time to score.)

Clustering of scores in certain formats with different symbols. Data from 387 patients were studied for clustering, including 119 patients who completed format T-3, 207 who completed format T-5, and 206 who completed format T-7

(some patients completed 2 of these formats (Table 2). In format T-5, with numbered squares at scores of 2, 4, 6, 8, and 10, 10.1% of patients scored 2.0, 10.6% scored 4.0, 9.2% scored 6.0, and 13.0% scored 8.0, compared to 5.9%, 3.4%, 0.8%, and 5.9%, respectively, on format T-3 with circles for these scores. In format T-7, which included numbers for all scores, but squares at 2.5, 5, 7.5, and 10, 12.1% of patients scored 2.5 and 17.0% scored 7.5, compared to 3.4% and 4.2% in format T-3, in which all scores were circles. These data, as well as studies with other formats (data not shown), indicate that labeling of intermittent numerical rating values and/or different intermittent symbols from circles, designed to facilitate scoring, were affected by “clustering,” i.e., a higher proportion of patients marked these compared to plain circles (Table 2).

Test-retest reliability. Data from 606 paired questionnaires

Table 2. Analysis of clustering in different formats of visual analog scale.

Position of Symbol	Format T-3, N = 119	Format T-5, N = 207	Format T-7, N = 206
0.0	5.0	8.7 (S)	10.7 (S)
0.5	13.4	3.4	2.4
1.0	10.1	3.9	2.9
1.5	3.4	3.4	2.9
2.0	5.9	10.1 (S)	3.4
2.5	3.4	1.0	12.1 (S)
3.0	4.2	4.3	1.5
3.5	8.4	1.0	3.4
4.0	3.4	10.6 (S)	2.4
4.5	5.9	0.5	4.9
5.0	5.9	10.6	15.5 (S)
5.5	0.0	1.0	0.5
6.0	0.8	9.2 (S)	3.9
6.5	5.0	2.9	1.0
7.0	4.2	5.3	2.4
7.5	4.2	2.4	17.0 (S)
8.0	5.9	13.0 (S)	2.4
8.5	2.5	2.4	1.5
9.0	4.2	0.5	1.9
9.5	3.4	1.0	0.0
10.0	0.8	4.8 (S)	7.3 (S)
Total	100%	100%	100%

S: Square instead of circles to facilitate scoring.

Table 1. Time to score MDHAQ function, pain, and patient global with various visual analog scale formats.

Format	Rheumatologist 1, Median	Rheumatologist 2, Median	Rheumatologist 3, Median	Rheumatologist 1, 2, 3, Median
T-1, traditional 10 cm VAS	18.9	16.8	11.9	15.6
T-2, 21 circles, no numbers	9.6	12.2	8.7	10.4
T-3, 21 circles, numbered at all scores	7.4	8.5	6.4	7.4
T-4, VAS circles, mark at 5.0	8.2	10.8	7.2	8.6
T-5, 21 symbols — 15 circles with 6 squares and numbers at 0, 2, 4, 6, 8, 10	11.1	10.2	8.4	10.2
T-6, 21 symbols — 18 circles with 3 diamonds at scores of 2.0, 4.0 and 6.5 to define categorical scale	8.2	12.4	7.8	8.3

were assessed for test-retest reliability, including 130 pairs of the 10 cm line format followed by the 21 circle format, 125 pairs of the 21 circle format followed by the 10 cm line format, 264 pairs of the 10 cm line format followed by another 10 cm line, and 87 pairs of the 21 circle format followed by another 21 circles. Correlation coefficients for test-retest reliability ranged from 0.83 to 0.94 ($p < 0.001$) (Figure 3) for the pain VAS, and 0.84 to 0.94 ($p < 0.001$) (Figure 4) for the global estimate VAS. The ICC was virtually identical to the Spearman correlation coefficient, all greater than 0.8 ($p < 0.001$).

Levels of agreement for the pain VAS were within 0.5 units for 49%–77% of patients, within 1 unit for 71%–93%

of patients, and within 2 units for 85%–97% for patients (Table 3). Levels of agreement for the global estimate VAS were within 0.5 units for 50%–77% of patients, within 1 unit for 70%–89% of patients, and within 2 units for 85%–94% of patients (Table 4). Highest levels of agreement were seen for 21 circles versus 21 circles, as might be expected with options for 21 scores rather than 101 with a 10 cm line.

Average differences were 0.016 for 10 cm line pain VAS compared to -0.017 for the 21 numbered circle pain VAS, and 0.24 for the 10 cm line global estimate VAS compared to 0.063 for the 21 numbered circle global VAS (Figure 5). Higher levels of differences were seen for comparisons of




Figure 3. Test-retest results of patient self-report of scores for pain on a 10 cm visual analog scale (VAS) and using 21 circles numbered at 0.5 intervals.




Figure 4. Test-retest results of patient self-report of scores for patient global estimate on a 10 cm visual analog scale (VAS) and using 21 circles numbered at 0.5 intervals.

line-to-circle and circle-to-line, although line-to-line and circle-to-circle comparisons were quite similar.

The SDD for the pain and global estimate VAS ranged from 1.77 to 3.54. The SDD was 1.92 for the 10 cm line pain VAS, 1.77 for the 21 numbered circle pain VAS, 1.98 for the 10 cm line global estimate VAS, and 2.09 for the 21 numbered circle global estimate VAS. Again, the SDD was higher for comparisons of line-to-circle and circle-to-line than for line-to-line or circle-to-circle VAS. Nonetheless, Spearman correlations, ICC, SDD, and limits of agreement were quite similar for the comparison of two 10 cm line VAS and two 21 circle VAS, completed by the same patients on the same day.

DISCUSSION

These data indicate similar results for a pain VAS and patient global estimate VAS, whether the VAS format involved 21 circles or a classic 10 cm line. The 21 circle format presents at least 3 advantages compared to the 10 cm line format: (1) an assessor can score the VAS without a ruler, saving about half the time, or about 8 seconds to score the 2 VAS on the MDHAQ; (2) the need to reproduce an exact 10 cm line in printing or photocopying questionnaires is eliminated, averting the problem of minor distortion frequently seen in photocopying or printing; (3) patients appear to have a better understanding of how to respond to the 21 circles compared to a 10 cm line, for which some patients

Table 3. Analysis of agreement between 2 formats of pain visual analog scales (VAS): 10 cm horizontal unmarked line and 21 circles numbered at 0.5 intervals.

Format 1	10 Cm Line	21 Numbered Circles	10 Cm Line	21 Numbered Circles
Format 2	21 Numbered Circles	10 Cm Line	10 Cm Line	21 Numbered Circles
Pain VAS	n = 130	n = 125	n = 264	n = 87
Spearman correlation*	0.83	0.94	0.94	0.96
Intraclass correlation*	0.83	0.93	0.94	0.96
SDD**	3.54	2.09	1.92	1.77
Average difference	-0.33	0.33	0.02	-0.02
Standard deviation	1.81	1.07	0.98	0.90
95% confidence interval	-3.87, 3.21	-1.76, 2.42	-1.90, 1.94	-1.79, 1.75
Difference ≤ 0.5	49%	51%	63%	77%
Difference ≤ 1	71%	73%	84%	92%
Difference ≤ 2	85%	95%	95%	97%

* All correlations significant at $p < 0.0001$. ** SDD: smallest detectable difference based upon Bland-Altman limits of agreement.

Table 4. Analysis of agreement between 2 formats of patient global estimate visual analog scales (VAS): 10 cm horizontal unmarked line and 21 circles numbered at 0.5 intervals.

Format 1	10 Cm Line	21 Numbered Circles	10 Cm Line	21 Numbered Circles
Format 2	21 Numbered Circles	10 Cm Line	10 Cm Line	21 Numbered Circles
Pain VAS	n = 130	n = 125	n = 264	n = 87
Spearman correlation*	0.84	0.87	0.92	0.94
Intraclass correlation*	0.80	0.87	0.93	0.94
SDD**	3.31	2.82	1.98	2.09
Average difference	-0.24	0.16	0.02	0.06
Standard deviation	1.69	1.44	1.01	1.06
95% confidence interval	-3.54, 3.07	-2.66, 2.97	-1.96, 2.01	-2.02, 2.15
Difference ≤ 0.5	53%	50%	58%	77%
Difference ≤ 1	72%	70%	80%	89%
Difference ≤ 2	85%	89%	95%	94%

* All correlations significant at $p < 0.0001$. ** SDD: smallest detectable difference based upon Bland-Altman limits of agreement.

write words or even sentences on the line¹¹, increasing the burden on the health professional to interpret the data. All 3 features facilitate scoring in usual care.

The 10 cm horizontal line format provides 101 possible scores compared to 21 possible scores in the 21 circle format. However, this reduction in possible scores appears satisfactory, in part because of evidence that individuals cannot necessarily discriminate more than 21 levels of differences in pain or estimate of global status¹⁸. Correlation of the 21 numbered circle format to itself is at least as high as for the 10 cm line to itself, or the 10 cm line to 21 numbered circle VAS formats.

VAS formats with intermittent numbers or different symbols were introduced initially to facilitate scoring. However, intermittent numbers and/or different symbols not only did not reduce the time to score the VAS compared with a 21 numbered circle format (Table 1), but also were associated with clustering of responses (Table 2). Some level of clustering, which would be anticipated to reduce sensitivity to change in status, was seen with all formats involving intermittent numbers and/or different symbols.

The comparisons of lines to lines and circles to circles, indicating correlations of 0.8 or higher, are similar to data reported by Lassere, *et al*¹⁹ and Kvien, *et al*²⁰. In some senses, as recognized by Lassere, *et al*, the SDD level found would likely be regarded as larger than anticipated by rheumatologists. Nonetheless, the SDD of the VAS as a 10 cm line or as 21 circles were virtually indistinguishable. Further, the correlations, ICC, and SDD of the VAS in either format, as a percentage of maximum score, were more favorable than those associated with tender and swollen joint counts in both of these studies.

A logarithmic scale may have offered a possible advantage of calculating a change in score from, say, 4 to 2, as identical metric to a change from 8 to 4, rather than as being half as great on a numeric scale. A slight advantage was seen in studies of adalimumab clinical trials according to a categorical logarithmic scale, even compared to a continuous arithmetic scale²¹. However, the difference was relatively minor, and would not appear to justify complexities in interpretation of logarithmic scale data in usual clinical care.




Figure 5. 95% Confidence bands around the scatterplot of test-retest differences.

Further, there was no saving in time to score the MDHAQ with categorical logarithmic (or arithmetic) scales, and clustering was introduced with changes of symbols to facilitate recognizing categorical cutpoints. Therefore, the 21 numbered circle format with an arithmetic scale appears to offer the optimal alternative to a 10 cm horizontal line.

It is possible to recognize and monitor clinical problems such as pain, global estimates, and fatigue qualitatively, rather than quantitatively. However, availability of quantitative data can add useful information and precision in patient care. In RA, it is now documented in FinRACO^{22,23}, TICO-

RA²⁴, BeST^{25,26}, and CAMERA²⁷ that intense quantitative monitoring of RA activity with a target of remission is associated with more rapid improvement and better outcomes than usual *gestalt* clinical care. Most visits to most rheumatologists do not include a formal quantitative joint count²⁸, but rather a careful nonquantitative joint examination. Simplified VAS scoring and a Routine Assessment of Patient Index Data (RAPID) score^{29,30} may enhance the capacity of rheumatologists to introduce quantitative assessment and monitoring of patients in usual clinical care.

ACKNOWLEDGMENT

The authors thank Drs. Till Uhlig and George Luta for helpful suggestions regarding statistical analyses and thoughtful review of the manuscript.

REFERENCES

1. Huskisson EC. Measurement of pain. *Lancet* 1974;2:1127-31.
2. Huskisson EC. Measurement of pain. *J Rheumatol* 1982;9:768-9.
3. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
4. Pincus T, Swearingen C, Wolfe F. Toward a Multidimensional Health Assessment Questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. *Arthritis Rheum* 1999;42:2220-30.
5. Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. *J Rheumatol* 2005;32:1261-6.
6. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988;15:1833-40.
7. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis Rheum* 1993;36:729-40.
8. Tugwell P, Boers M. OMERACT Committee. Proceedings of the OMERACT Conferences on outcome measures in rheumatoid arthritis clinical trials, Maastricht, Netherlands. *J Rheumatol* 1993;20:527-91.
9. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional Health Assessment Questionnaire for standard care of patients with rheumatic diseases. *J Rheumatol* 2005;32:1432-9.
10. Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. *Arthritis Care Res* 2003;49:59-63.
11. Callahan LF, Brooks RH, Summey JA, Pincus T. Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analogue pain scale. *Arthritis Rheum* 1987;30:630-6.
12. Huskisson EC. Visual analogue scales. In: Melzack R, editor. *Pain measurement and assessment*. New York: Raven Press; 1983:33-7.
13. Mason JH, Anderson JJ, Meenan RF, Haralson KM, Lewis-Stevens D, Kaine JL. The Rapid Assessment of Disease Activity in Rheumatology (RADAR) questionnaire: validity and sensitivity to change of a patient self-report measure of joint count and clinical status. *Arthritis Rheum* 1992;35:156-62.
14. Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research. *Arthritis Rheum* 1995;38:795-8.
15. Felson DT. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. *J Rheumatol* 1993;20:531-4.
16. Yazici Y, Bergman M, Pincus T. Time to score various measures to assess rheumatoid arthritis. *J Rheumatol* 2008;35:603-9; Epub Mar 1.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;i:307-10.
18. Jensen MP, Turner JA, Romano JM. What is the maximum number of levels needed in pain intensity measurement? *Pain* 1994;58:387-92.
19. Lassere MND, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: Implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. *J Rheumatol* 2001;28:892-903.
20. Kvien TK, Mowinckel P, Heiberg T, et al. Performance of health status measures with a pen based personal digital assistant. *Ann Rheum Dis* 2005;64:1480-4.
21. Pincus T, Amara I, Koch GG. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. *Arthritis Rheum* 2005;52:1031-6.
22. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo Trial Group. *Lancet* 1999;353:1568-73.
23. Puolakka K, Kautiainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized followup trial. *Arthritis Rheum* 2004;50:55-62.
24. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004;364:263-9.
25. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum* 2005;52:3381-90.
26. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007;146:406-15.
27. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007;66:1443-9.
28. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. *Ann Rheum Dis* 2006;65:820-2.
29. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. *Rheumatology Oxford* 2008;47:345-9.
30. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). *Best Pract Res Clin Rheumatol* 2007;21:789-804.